Honey and Nigella Sativa in COVID-19 Prophylaxis

Phase 2

• Conditions: Covid19
• Interventions: Other: Placebo; Drug: Honey; Drug: Nigella sativa seed

• Registration Number: NCT04767087
• Lead Sponsor: Sohaib Ashraf

Brief Summary

Honey and Nigella sativa has established antiviral, antibacterial, anti-inflammatory, and immunomodulatory roles. So it is planned to test for its prophylaxis

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-02-20
• Study First Submitted QC: 2021-02-20
• Study First Posted: 2021-02-23
• Study Start: 2021-03-05
• Status Verified: 2021-07
• Last Update Submitted: 2021-07-01
• Last Update Posted: 2021-07-02
• Primary Completion: 2022-02-15
• Study Completion: 2022-04-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Health care professionals Post-exposure COVID-19

Exclusion Criteria

• Multi-organ failure active COVID-19

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Honey and Nigella sativa Arm	Nigella sativa seed	0.5 g/kg/day honey 40 mg/Kg/day Nigella sativa seeds
Placebo Arm	Placebo	empty capsule with sugar water
Honey and Nigella sativa Arm	Honey	0.5 g/kg/day honey 40 mg/Kg/day Nigella sativa seeds

Primary Outcome Measures

Name	Time	Method
SARS-CoV-2 infection rate	14 days	RT-PCR SARS-CoV-2

Trial Locations

Locations (1)

Shaikh Zayed Post-Graduate Medical Institute; 🇵🇰 Lahore, MA, Pakistan